Lineage Cell (Israel) Market Value

LCTX Stock  ILA 222.50  11.30  5.35%   
Lineage Cell's market value is the price at which a share of Lineage Cell trades on a public exchange. It measures the collective expectations of Lineage Cell Therapeutics, investors about its performance. Lineage Cell is trading at 222.50 as of the 29th of November 2024, a 5.35% up since the beginning of the trading day. The stock's open price was 211.2.
With this module, you can estimate the performance of a buy and hold strategy of Lineage Cell Therapeutics, and determine expected loss or profit from investing in Lineage Cell over a given investment horizon. Check out Lineage Cell Correlation, Lineage Cell Volatility and Lineage Cell Alpha and Beta module to complement your research on Lineage Cell.
Symbol

Please note, there is a significant difference between Lineage Cell's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lineage Cell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lineage Cell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lineage Cell 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Lineage Cell's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Lineage Cell.
0.00
10/30/2024
No Change 0.00  0.0 
In 31 days
11/29/2024
0.00
If you would invest  0.00  in Lineage Cell on October 30, 2024 and sell it all today you would earn a total of 0.00 from holding Lineage Cell Therapeutics, or generate 0.0% return on investment in Lineage Cell over 30 days. Lineage Cell is related to or competes with Rapac Communication, Batm Advanced, Tower Semiconductor, YH Dimri, and Bezeq Israeli. Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing thera... More

Lineage Cell Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Lineage Cell's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Lineage Cell Therapeutics, upside and downside potential and time the market with a certain degree of confidence.

Lineage Cell Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Lineage Cell's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Lineage Cell's standard deviation. In reality, there are many statistical measures that can use Lineage Cell historical prices to predict the future Lineage Cell's volatility.
Hype
Prediction
LowEstimatedHigh
11.13222.5022,472
Details
Intrinsic
Valuation
LowRealHigh
8.50170.0522,420
Details
Naive
Forecast
LowNextHigh
1.3768.52215.59
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
24.00273.29522.58
Details

Lineage Cell Therape Backtested Returns

Lineage Cell is out of control given 3 months investment horizon. Lineage Cell Therape has Sharpe Ratio of 0.13, which conveys that the firm had a 0.13% return per unit of risk over the last 3 months. We were able to analyze twenty-nine different technical indicators, which can help you to evaluate if expected returns of 18.56% are justified by taking the suggested risk. Use Lineage Cell Therape Downside Deviation of 17.27, risk adjusted performance of 0.1029, and Mean Deviation of 303.09 to evaluate company specific risk that cannot be diversified away. Lineage Cell holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -116.88, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Lineage Cell are expected to decrease by larger amounts. On the other hand, during market turmoil, Lineage Cell is expected to outperform it. Use Lineage Cell Therape sortino ratio, maximum drawdown, and the relationship between the total risk alpha and treynor ratio , to analyze future returns on Lineage Cell Therape.

Auto-correlation

    
  -0.06  

Very weak reverse predictability

Lineage Cell Therapeutics, has very weak reverse predictability. Overlapping area represents the amount of predictability between Lineage Cell time series from 30th of October 2024 to 14th of November 2024 and 14th of November 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Lineage Cell Therape price movement. The serial correlation of -0.06 indicates that barely 6.0% of current Lineage Cell price fluctuation can be explain by its past prices.
Correlation Coefficient-0.06
Spearman Rank Test-0.08
Residual Average0.0
Price Variance20.5 K

Lineage Cell Therape lagged returns against current returns

Autocorrelation, which is Lineage Cell stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Lineage Cell's stock expected returns. We can calculate the autocorrelation of Lineage Cell returns to help us make a trade decision. For example, suppose you find that Lineage Cell has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
   Current and Lagged Values   
       Timeline  

Lineage Cell regressed lagged prices vs. current prices

Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Lineage Cell stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Lineage Cell stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Lineage Cell stock over time.
   Current vs Lagged Prices   
       Timeline  

Lineage Cell Lagged Returns

When evaluating Lineage Cell's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Lineage Cell stock have on its future price. Lineage Cell autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Lineage Cell autocorrelation shows the relationship between Lineage Cell stock current value and its past values and can show if there is a momentum factor associated with investing in Lineage Cell Therapeutics,.
   Regressed Prices   
       Timeline  

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Lineage Stock

Lineage Cell financial ratios help investors to determine whether Lineage Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lineage with respect to the benefits of owning Lineage Cell security.